Amendment of Drugs Rules 1945 for inclusion of Acitretin in schedule H of the Drugs Rules 1945

## Report on Amendment to Drugs Rules, 1945 **1. Executive Summary:** This report analyzes a notification from the Ministry of Health and Family Welfare, Government of India, published on February 1st, 2022, which proposes an amendment to the Drugs Rules, 1945. The amendment, specifically adding "Acitretin" to Schedule H of the Drugs Rules, 1945, indicating a change in how this drug is regulated. This report details the likely implications of this change based solely on the provided text. **2. Introduction:** This report aims to provide a clear and concise overview of a proposed amendment to the Drugs Rules, 1945, as announced in a notification from the Ministry of Health and Family Welfare on February 1st, 2022. The analysis is based solely on the information provided within the given notification text. **3. Policy Overview:** * **Original Policy:** Drugs Rules, 1945 * **Core Objective(s):** From the provided text, the core objective of the original Drugs Rules, 1945, is inferred to be the regulation of drugs within India. This is evidenced by the amendment process, which involves adding to or modifying these rules. The amendment indicates the rules aim to keep drug regulations current. **4. Background and Rationale:** This is an amendment to the Drugs Rules, 1945. The likely reason for this specific amendment is the need to include Acitretin, a specific drug, within the regulatory framework of the Drugs Rules, 1945. Adding it to Schedule H likely implies the need for tighter controls or specific requirements related to its sale and use, likely due to safety concerns or considerations regarding its therapeutic application. **5. Key Provisions / Changes:** This amendment focuses on a specific change to Schedule H of the Drugs Rules, 1945. * **Specific Part of Original Policy Changed:** Schedule H of the Drugs Rules, 1945. * **New Rule/Provision:** The amendment adds "552. Acitretin" to Schedule H. * **Difference/Effect of the Change:** Adding Acitretin to Schedule H likely subjects this drug to the regulations and requirements specified for drugs listed under that schedule. While the text does not specify the exact requirements of Schedule H, it can be inferred that it places specific controls or restrictions on the drug's availability, sale, and potentially its prescription and usage. This could involve requiring a prescription for dispensing, special labeling requirements, or restrictions on advertising. The specific impact is dependent on the regulations defined within Schedule H. **6. Target Audience and Stakeholders:** Based on the provided text, the target audience and stakeholders directly affected by this amendment include: * Pharmaceutical manufacturers and distributors dealing with Acitretin. * Pharmacists involved in dispensing Acitretin. * Medical practitioners who prescribe Acitretin. * Patients who use Acitretin. * Regulatory bodies responsible for enforcing the Drugs Rules, 1945. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Health and Family Welfare, along with the Drugs Technical Advisory Board, are responsible for implementing and overseeing this amendment. The Under Secretary Drugs, mentioned in the notification, is a key point of contact. * **Timelines/Procedures:** The text specifies a 30-day period for public comment and suggestion, suggesting a defined timeline for the finalization and implementation of the amendment. The rules shall come into force on the date of their final publication in the Official Gazette. * **Specific to Changes:** Pharmaceutical companies will likely need to update their processes and documentation to comply with the requirements for Acitretin under Schedule H once the amendment comes into effect. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of adding Acitretin to Schedule H is to enhance the safety and appropriate use of the drug. This could lead to: * Increased control over the distribution and dispensing of Acitretin. * Improved monitoring of its usage and potential adverse effects. * Reduced risk of misuse or inappropriate prescribing. * Ultimately, improved patient safety. **9. Conclusion:** The amendment to the Drugs Rules, 1945, adding Acitretin to Schedule H, signifies a change in its regulatory status. This change likely aims to enhance control over the drug's availability and use, with the overarching goal of safeguarding patient safety. Affected industry stakeholders should familiarize themselves with the specific requirements of Schedule H to ensure compliance once the amendment is finalized and implemented.

Key Entities Referenced